Clinical Trial

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with primary progressive multiple sclerosis (PPMS).
Protocol Amendment History 3 changes
critical Trial status changed: RECRUITING → ACTIVE_NOT_RECRUITING 2026-07-07
notable Primary completion pushed: 2027-03-12 -> 2027-12-31 2026-07-07
minor Completion pushed: 2027-04-23 -> 2028-12-31 2026-07-07
Trial Details
NCT Number NCT07483450
Lead Sponsor Hoffmann-La Roche
Conditions Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Enrollment 60 participants
Start Date 2025-07-04
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-06